PHARMA EXPERTS CALL FOR SMART REGULATION ON ALZHEIMER’S DISEASE, TO AID DRUG DEVELOPMENT
December 1st, 2014
DEVELOPING medicines that reverse or even slow Alzheimer’s disease has proved to be a tough task for the world’s pharma sector, and it is looking for ways to ensure regulation does not pose an additional and maybe insurmountable barrier. A workshop on Alzheimer’s disease (AD), at the London headquarters of the European Medicines Agency (EMA), has heard from specialists debating the latest advances in understanding of the pathophysiology of Alzheimer’s and the discovery of disease-modifying treatment targets. Other topics included the changing diagnostic ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.